192 related articles for article (PubMed ID: 23935247)
21. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
Kashfi K; Chattopadhyay M; Kodela R
Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
[TBL] [Abstract][Full Text] [Related]
22. The effect of acetylshikonin isolated from Lithospermum canescens roots on tumor-induced cutaneous angiogenesis.
Pietrosiuk A; Furmanowa M; Skopińiska-Rózewska E; Sommer E; Skurzak H; Bany J
Acta Pol Pharm; 2004; 61(5):379-82. PubMed ID: 15747695
[TBL] [Abstract][Full Text] [Related]
23. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer.
Oida Y; Gopalan B; Miyahara R; Inoue S; Branch CD; Mhashilkar AM; Lin E; Bekele BN; Roth JA; Chada S; Ramesh R
Mol Cancer Ther; 2005 Feb; 4(2):291-304. PubMed ID: 15713900
[TBL] [Abstract][Full Text] [Related]
24. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Tinsley HN; Gary BD; Thaiparambil J; Li N; Lu W; Li Y; Maxuitenko YY; Keeton AB; Piazza GA
Cancer Prev Res (Phila); 2010 Oct; 3(10):1303-13. PubMed ID: 20876730
[TBL] [Abstract][Full Text] [Related]
25. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells.
Nikitakis NG; Hamburger AW; Sauk JJ
Cancer Res; 2002 Feb; 62(4):1004-7. PubMed ID: 11861373
[TBL] [Abstract][Full Text] [Related]
26. Sulindac activates NF-κB signaling in colon cancer cells.
Mladenova D; Pangon L; Currey N; Ng I; Musgrove EA; Grey ST; Kohonen-Corish MR
Cell Commun Signal; 2013 Oct; 11():73. PubMed ID: 24083678
[TBL] [Abstract][Full Text] [Related]
27. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB.
Berman KS; Verma UN; Harburg G; Minna JD; Cobb MH; Gaynor RB
Clin Cancer Res; 2002 Feb; 8(2):354-60. PubMed ID: 11839649
[TBL] [Abstract][Full Text] [Related]
28. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
Lim JT; Piazza GA; Han EK; Delohery TM; Li H; Finn TS; Buttyan R; Yamamoto H; Sperl GJ; Brendel K; Gross PH; Pamukcu R; Weinstein IB
Biochem Pharmacol; 1999 Oct; 58(7):1097-107. PubMed ID: 10484067
[TBL] [Abstract][Full Text] [Related]
29. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.
Moon Y; Bottone FG; McEntee MF; Eling TE
Mol Cancer Ther; 2005 Oct; 4(10):1551-8. PubMed ID: 16227405
[TBL] [Abstract][Full Text] [Related]
30. Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac.
Akashi H; Han HJ; Iizaka M; Nakamura Y
Int J Cancer; 2000 Dec; 88(6):873-80. PubMed ID: 11093808
[TBL] [Abstract][Full Text] [Related]
31. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines.
Han EK; Arber N; Yamamoto H; Lim JT; Delohery T; Pamukcu R; Piazza GA; Xing WQ; Weinstein IB
Breast Cancer Res Treat; 1998 Apr; 48(3):195-203. PubMed ID: 9598866
[TBL] [Abstract][Full Text] [Related]
32. New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen.
Fujiki H; Suganuma M; Kurusu M; Okabe S; Imayoshi Y; Taniguchi S; Yoshida T
Mutat Res; 2003; 523-524():119-25. PubMed ID: 12628509
[TBL] [Abstract][Full Text] [Related]
33. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.
Agarwal B; Rao CV; Bhendwal S; Ramey WR; Shirin H; Reddy BS; Holt PR
Gastroenterology; 1999 Oct; 117(4):838-47. PubMed ID: 10500066
[TBL] [Abstract][Full Text] [Related]
34. PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells.
Nikitakis NG; Hebert C; Lopes MA; Reynolds MA; Sauk JJ
Int J Cancer; 2002 Apr; 98(6):817-23. PubMed ID: 11948457
[TBL] [Abstract][Full Text] [Related]
35. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
[TBL] [Abstract][Full Text] [Related]
36. Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice.
Greenspan EJ; Nichols FC; Rosenberg DW
Cancer Prev Res (Phila); 2010 Sep; 3(9):1187-97. PubMed ID: 20716632
[TBL] [Abstract][Full Text] [Related]
37. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.
Itano O; Yang K; Fan K; Kurihara N; Shinozaki H; Abe S; Jin B; Gravaghi C; Edelmann W; Augenlicht L; Kopelovich L; Kucherlapati R; Lamprecht S; Lipkin M
Carcinogenesis; 2009 Nov; 30(11):1923-6. PubMed ID: 19755659
[TBL] [Abstract][Full Text] [Related]
38. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.
Williams CS; Goldman AP; Sheng H; Morrow JD; DuBois RN
Neoplasia; 1999 Jun; 1(2):170-6. PubMed ID: 10933052
[TBL] [Abstract][Full Text] [Related]
39. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
[TBL] [Abstract][Full Text] [Related]
40. Effects of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse.
Illanes J; Dabancens A; Acuña O; Fuenzalida M; Guerrero A; Lopez C; Lemus D
Biol Res; 2002; 35(3-4):339-45. PubMed ID: 12462986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
